Literature DB >> 26404603

Draft Genome Sequence of the First NDM-1-Producing Providencia stuartii Strain Isolated in Portugal.

Vera Manageiro1, Daniel A Sampaio2, Patrícia Pereira3, Paulo Rodrigues3, Luís Vieira2, Carlos Palos3, Manuela Caniça4.   

Abstract

We report here the draft genome sequence of the first NDM-1-producing Providencia stuartii strain isolated in Portugal. Sequence analyses revealed the presence of an incompatibility group A/C2 (IncA/C2) plasmid and of diverse acquired genes conferring resistance to β-lactams, aminoglycosides, tetracycline, macrolides, chloramphenicol, and sulfonamides. This sequence contributes to the evaluation of the spread of NDM-1 producers.
Copyright © 2015 Manageiro et al.

Entities:  

Year:  2015        PMID: 26404603      PMCID: PMC4582579          DOI: 10.1128/genomeA.01077-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Providencia stuartii, an opportunistic pathogen typically associated with urinary infections, has intrinsic resistance to antibiotics considered to be of last resort, such as colistin and tigecycline (1, 2). Moreover, carbapenemase producers have been reported, which can become of higher concern (3–5). Five NDM-1-producing P. stuartii isolates were obtained during an outbreak detected in a Portuguese hospital. One isolate, P. stuartii INSRA21868, recovered from a urine sample from an 88-year-old male patient admitted to the intensive care unit due to an enterocutaneous fistula, was selected for genetic characterization using whole-genome sequencing (WGS). DNA was extracted from an overnight grown culture using the QIAamp DNA minikit (Qiagen), according to the manufacturer’s instructions. Libraries were prepared from 1 ng of genomic DNA using the Nextera XT DNA sample preparation kit (Illumina), according to the manufacturer’s instructions. WGS was performed using 150-bp paired-end reads on a MiSeq (Illumina). The sequence reads were trimmed and filtered according to quality criteria and de novo assembled into contigs and subsequently into scaffolds by means of CLC Genomics Workbench 8.0.1 (Qiagen, Aarhus, Denmark). The analysis yielded 59 contigs ranging from 246 bp to 365,814 bp, with a minimum of 100-fold coverage. The draft genome contains a total assembly length of 4,438,644 bp, with a mean coverage of about 290-fold; the G+C content was 43.1%. All de novo contigs were searched against the GenBank database nucleotide collection (nr/nt) using Mega BLAST, with seven contigs (15/41/43/47/48/49/53) mapping against plasmid sequences deposited there; the remaining sequence aligned to the P. stuartii genome (accession no. NZ_CP008920 and CP003488). The nucleotide sequence was annotated using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) (http://www.ncbi.nlm.nih.gov/genome/annotation_prok/). The numbers of annotated features were as follows: 3,962 coding sequences (CDSs), 4,146 genes, 20 noncoding RNAs (ncRNAs), 4 rRNAs, and 72 tRNAs. In silico antimicrobial resistance analyses using ResFinder version 2.1 (6), with a threshold of 90% identity and a minimum length of 40%, revealed genes conferring resistance to β-lactams (blaNDM-1 [contig 53], blaCMY-4 [contig 15], and ΔblaDHA-1 [contig 53]), aminoglycosides (aac(2′)-Ia [contig 19] and armA [contig 49]), tetracycline (tetB [contig 9]), macrolides (mphE and msrE [contig 49]), chloramphenicol (catB3 [contig 2]), and sulfonamides (sul1 [contig 49]). PlasmidFinder version 1.2 (7) analyses revealed the presence of incompatibility group A/C2 (IncA/C2), which has been associated with a wide dissemination of blaNDM-1. The NDM-1-encoding gene was found in the 3,360-bp-long contig 53, with a mean coverage of about 136-fold and a G+C content of 57.9%. In the 3′ region, the blaNDM-1 gene was adjacent to a bleomycin resistance-encoding gene (bleMBL), followed by a trpF and part of the blaDHA-1-ampR region. The ISAba125 element upstream of blaNDM-1 was interrupted by an IS26 element. Four plasmids harbored by different Enterobacteriaceae isolates showed the highest identities with this genetic structure (accession numbers KJ187752, LN831185, JX988621, and HQ451074). Overall, this genome sequence contributes to the evaluation of the global molecular epidemiology and spread of NDM-1 producers.

Nucleotide sequence accession numbers.

This whole-genome sequencing shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. LGYB00000000. The version described in this paper is version LGYB01000000.
  7 in total

1.  Complete sequence of a novel 178-kilobase plasmid carrying bla(NDM-1) in a Providencia stuartii strain isolated in Afghanistan.

Authors:  Patrick McGann; Jun Hang; Robert J Clifford; Yu Yang; Yoon I Kwak; Robert A Kuschner; Emil P Lesho; Paige E Waterman
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Characterization of multiple NDM-1-producing Enterobacteriaceae isolates from the same patient.

Authors:  Nathalie Tijet; David Richardson; Gregory MacMullin; Samir N Patel; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Growing prevalence of Providencia stuartii associated with the increased usage of colistin at a tertiary health care center.

Authors:  Kayoko Hayakawa; Dror Marchaim; George W Divine; Jason M Pogue; Sarwan Kumar; Paul Lephart; Ken Risko; Jack D Sobel; Keith S Kaye
Journal:  Int J Infect Dis       Date:  2012-07-19       Impact factor: 3.623

4.  Genetic features of blaNDM-1-positive Enterobacteriaceae.

Authors:  Laurent Poirel; Laurent Dortet; Sandrine Bernabeu; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

5.  In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing.

Authors:  Alessandra Carattoli; Ea Zankari; Aurora García-Fernández; Mette Voldby Larsen; Ole Lund; Laura Villa; Frank Møller Aarestrup; Henrik Hasman
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Natural antibiotic susceptibility of Providencia stuartii, P. rettgeri, P. alcalifaciens and P. rustigianii strains.

Authors:  I Stock; B Wiedemann
Journal:  J Med Microbiol       Date:  1998-07       Impact factor: 2.472

7.  Identification of acquired antimicrobial resistance genes.

Authors:  Ea Zankari; Henrik Hasman; Salvatore Cosentino; Martin Vestergaard; Simon Rasmussen; Ole Lund; Frank M Aarestrup; Mette Voldby Larsen
Journal:  J Antimicrob Chemother       Date:  2012-07-10       Impact factor: 5.790

  7 in total
  13 in total

Review 1.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

2.  Genomic Analysis of two NDM-1 Providencia stuartii Strains Recovered from a Single Patient.

Authors:  Amparo Hoard; Sabrina Montaña; Alessandro Moriano; Jennifer S Fernandez; German M Traglia; Cecilia Quiroga; Agustina Franchi; Emilia Cohen; Cecilia Corigliano; Marisa Almuzara; Maria Soledad Ramirez
Journal:  Curr Microbiol       Date:  2020-10-13       Impact factor: 2.188

3.  Draft Genome Sequence of an Escherichia coli Strain Isolated from a Gallus gallus Broiler Producing the Novel CTX-M-166 Variant.

Authors:  Vera Manageiro; Lurdes Clemente; Sílvia Duarte; Luís Vieira; Manuela Caniça
Journal:  Genome Announc       Date:  2016-10-06

4.  Providencia stuartii form biofilms and floating communities of cells that display high resistance to environmental insults.

Authors:  Mariam El Khatib; Que-Tien Tran; Chady Nasrallah; Julie Lopes; Jean-Michel Bolla; Michel Vivaudou; Jean-Marie Pagès; Jacques-Philippe Colletier
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

Review 5.  First literature review of carbapenem-resistant Providencia.

Authors:  M Abdallah; A Balshi
Journal:  New Microbes New Infect       Date:  2018-06-04

6.  Molecular Insights into Antimicrobial Resistance Traits of Multidrug Resistant Enteric Pathogens isolated from India.

Authors:  Pawan Kumar; Satyabrata Bag; Tarini Shankar Ghosh; Prasanta Dey; Mayanka Dayal; Bipasa Saha; Jyoti Verma; Archana Pant; Shruti Saxena; Anbumani Desigamani; Preety Rana; Dhirendra Kumar; Naresh C Sharma; Pranita Hanpude; Tushar K Maiti; Asish K Mukhopadhyay; Rupak K Bhadra; G Balakrish Nair; Thandavarayan Ramamurthy; Bhabatosh Das
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

7.  Molecular Epidemiology and Risk Factors of Carbapenemase-Producing Enterobacteriaceae Isolates in Portuguese Hospitals: Results From European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE).

Authors:  Vera Manageiro; Raquel Romão; Inês Barata Moura; Daniel A Sampaio; Luís Vieira; Eugénia Ferreira; Manuela Caniça
Journal:  Front Microbiol       Date:  2018-11-27       Impact factor: 5.640

8.  Distribution of NDM1 Carbapenemase-Producing Proteeae Strains on High-Risk Hospital Wards.

Authors:  Maria Rus; Monica Licker; Corina Musuroi; Edward Seclaman; Delia Muntean; Natalia Cirlea; Alina Tamas; Silvana Vulpie; Florin George Horhat; Luminita Baditoiu
Journal:  Infect Drug Resist       Date:  2020-12-31       Impact factor: 4.003

9.  Genetic Background and Expression of the New qepA4 Gene Variant Recovered in Clinical TEM-1- and CMY-2-Producing Escherichia coli.

Authors:  Vera Manageiro; David Félix; Daniela Jones-Dias; Daniel A Sampaio; Luís Vieira; Luísa Sancho; Eugénia Ferreira; Manuela Caniça
Journal:  Front Microbiol       Date:  2017-10-09       Impact factor: 5.640

10.  Genomic Epidemiology of NDM-1-Encoding Plasmids in Latin American Clinical Isolates Reveals Insights into the Evolution of Multidrug Resistance.

Authors:  Ricaurte Alejandro Marquez-Ortiz; Leanne Haggerty; Narda Olarte; Carolina Duarte; Ulises Garza-Ramos; Jesus Silva-Sanchez; Betsy E Castro; Eby M Sim; Mauricio Beltran; María V Moncada; Alberto Valderrama; Jaime E Castellanos; Ian G Charles; Natasha Vanegas; Javier Escobar-Perez; Nicola K Petty
Journal:  Genome Biol Evol       Date:  2017-06-01       Impact factor: 3.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.